Products > Ophthalmology > VABYSMO® (Faricimab) > Mode of Action
Mode of Action
VABYSMO is the first approved bispecific molecule uniquely engineered
to target VEGF-A and Ang-2 to restore vascular stability1,2
Fc region: Fragment crystallisable region is the tail region of the antibody.
Explore this innovative bispecific module
Mode of action
Contact
Roche Pharmaceuticals (Israel) Ltd.
6 Hacharash St. Hod Hasharon
Telephone: 09-9737777
E-mail: israel.ophthalmology@roche.com
-
List of abbreviations
- AEs: adverse events
- AMD: age-related macular degeneration
- Ang-2: angiopoietin-2
- APTC: Anti-Platelet Trialists’ Collaboration
- BCVA: best corrected visual acuity
- CNV: choroidal neovascularisation
- CST: central subfield thickness
- DME: diabetic macular oedema
- DR: diabetic retinopathy
- DRSS: diabetic retinopathy severity scale
- ETDRS: early treatment diabetic retinopathy study
- ETDRS-DRSS: early treatment diabetic retinopathy study diabetic retinopathy severity scale
- Fc: fragment crystallisable
- FFA: fundus fluorescein angiography
- HbA1c: glycated haemoglobin
- IOI: intraocular inflammation
- ILM: inner limiting membrane
- ILM-RPE: inner limiting membrane-retinal pigment epithelium
- IRF: intraretinal fluid
- IVT: intravitreal
- nAMD: neovascular age-related macular degeneration
- NPDR: non-proliferative diabetic retinopathy
- PDR: proliferative diabetic retinopathy
- RAP: retinal angiomatous proliferation
- RPE: retinal pigment epithelium
- SAE: serious adverse events
- SD: standard deviation
- SRF: subretinal fluid
- VEGF: vascular endothelial growth factor
- VEGF-A: vascular endothelial growth factor-A
-
References
1. Heier JS, et al. Lancet. 2022;399(10326):729-40.
2. Wykoff CC, et al. Lancet. 2022;399(10326):741-755.
3. Holz FG, et al. Presented at EURETINA 2022, Hamburg, Germany, 1–4 September 2022.
4. Schlottmann PG, et al. Presented at EURETINA 2022, Hamburg, Germany, 1–4 September 2022.
5. Ciulla TA, et al. Ophthalmol Retina. 2020;4(1):19–30.
6. Skelly A, et al. Vision (Basel). 2019;3:41.
7. DeCroos FC, et al. Am J Ophthalmol. 2017;180:142–50.
8. Ciulla TA, et al. Br J Ophthalmol. 2021;105(2):216–221.
9. Heier JS, et al. Retina. 2021;41(1):1–19.
10. Regula JT, et al. EMBO Mol Med. 2016;8:1265–88.
11. Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635–661.
12. Joussen AM, et al. Eye. 2021;35:1305–1316.
13. Khanani AM, et al. Ophthalmol Sci. 2021;1(4):100076.
14. Priglinger SG, et al. Presented at the Macula Society 45th Annual Meeting, Berlin, Germany, June 8–11, 2022.
15. Data on File. nAMD. Change from Baseline in CST. October 2020.
16. Data on File. nAMD. Summary of Clinical Safety. June 2022.
17. Eter N, et al. Ophthalmol Sci. 2022;2(1):100111.
18. Heier JS, et al. Presented at the Annual Meeting of the American Academy of Ophthalmology Retina Subspecialty Day 2021, New Orleans, LA, November 12–13, 2021.
19. Data on File. DME. Change from Baseline in CST. November 2021.
20. Baumal CR, et al. Presented at the Association for Research in Vision and Ophthalmology, Denver, CO, May 1–4, 2022.
21. Data on File. DME. Summary of Clinical Safety. February 2022.
22. Figueroa MS, et al. Presented at the 22nd EURETINA Congress, Hamburg, Germany, September 1–4, 2022.
23. Data on File. nAMD. Patient Case. September 2022.
24. Data on File. DME. Patient Case. September 2022.
25. Roche Data on File
Do you have general questions? Feel free to contact us.
Roche Pharmaceuticals (Israel) Ltd.
6 Hacharash St. Hod Hasharon
Telephone: 09-9737777
E-mail: israel.ophthalmology@roche.com